Taysha Gene Therapies Stock Forecast, Price & News

-1.05 (-4.22 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $23.86
50-Day Range
MA: $23.75
52-Week Range
Now: $23.86
Volume89,203 shs
Average Volume91,715 shs
Market Capitalization$900.98 million
P/E RatioN/A
Dividend YieldN/A
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Taysha Gene Therapies logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TSHA
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$900.98 million
Next Earnings Date6/2/2021 (Estimated)
OptionableNot Optionable


Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase
April 15, 2021 |
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19
April 12, 2021 |
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54
March 29, 2021 |
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $22.47
March 25, 2021 |
See More Headlines


Overall MarketRank

1.77 out of 5 stars

Medical Sector

175th out of 2,025 stocks

Biological Products, Except Diagnostic Industry

23rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
-1.05 (-4.22 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TSHA News and Ratings via Email

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Is Taysha Gene Therapies a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Taysha Gene Therapies stock.
View analyst ratings for Taysha Gene Therapies
or view top-rated stocks.

What stocks does MarketBeat like better than Taysha Gene Therapies?

Wall Street analysts have given Taysha Gene Therapies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Taysha Gene Therapies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Taysha Gene Therapies' next earnings date?

Taysha Gene Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for Taysha Gene Therapies

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) posted its quarterly earnings results on Tuesday, March, 2nd. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.68.
View Taysha Gene Therapies' earnings history

What price target have analysts set for TSHA?

6 equities research analysts have issued 1 year price targets for Taysha Gene Therapies' stock. Their forecasts range from $31.00 to $67.50. On average, they anticipate Taysha Gene Therapies' stock price to reach $43.92 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies
or view top-rated stocks among Wall Street analysts.

Who are Taysha Gene Therapies' key executives?

Taysha Gene Therapies' management team includes the following people:
  • Mr. R. A. Session II, Founder, Pres, CEO & Director (Age 42, Pay $634.63k)
  • Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 43, Pay $756.38k)
  • Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 51, Pay $501.78k)
  • Mr. Fred Porter Ph.D., Chief Technical Officer
  • Mr. Jim Rouse, Chief Information Officer
  • Dr. Kimberly Lee D.O., Sr. VP of Corp. Communications & Investor Relations
  • Mr. Timothy J. Douros J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Tracy M. Porter, Chief People Officer
  • Ms. Emily McGinnis M.P.H., Chief Patient Officer & Head of Gov. Affairs
  • Ms. Mishima Gerhart, Chief Regulatory Officer & Head of Quality

Who are some of Taysha Gene Therapies' key competitors?

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

When did the company's lock-up period expire?

Taysha Gene Therapies' lock-up period expired on Tuesday, March 23rd. Taysha Gene Therapies had issued 7,869,566 shares in its initial public offering on September 24th. The total size of the offering was $157,391,320 based on an initial share price of $20.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $23.86.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies has a market capitalization of $900.98 million.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies employs 38 workers across the globe.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is

Where are Taysha Gene Therapies' headquarters?

Taysha Gene Therapies is headquartered at 2280 Inwood Road, DALLAS TX, 75235.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.